Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

This study found that sexual trauma, particularly occurring between ages 5-7, was significantly associated with blunted hair cortisol levels, revealing a potential critical developmental stage affecting HPA axis function. No significant link was observed between cortisol reactivity and other adverse childhood experiences or stressors.

This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.

This review discusses the sexual side effects of long-term finasteride usage in men, noting varied reports of sexual dysfunction which typically improve over time; it presents no new experimental data.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This study suggests that gendered social factors, in addition to biological differences, contribute significantly to sex disparities in adverse drug event reports, with patient and event type influencing observed differences.

In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.

This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.

This review discusses the occurrence of persistent sexual, physical, neurological, and psychiatric side effects known as post-finasteride syndrome after 5x-reductase inhibitor treatment, and emphasizes the importance of evaluating these risks for patients with benign prostatic hyperplasia or androgenic alopecia.

This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.

This study found that patients using finasteride were up to twice as likely to experience sexual dysfunction, including ejaculation disorder, decreased libido, and impotence, compared to those not using the drug.

This study found that men experiencing long-term symptoms after finasteride use for androgenetic alopecia frequently reported loss of penis sensitivity and anhedonia, among other effects, indicating potential post-finasteride syndrome.

In this study, men under 40 using finasteride for alopecia who experienced persistent sexual side effects and insomnia were reportedly at risk for suicide.

This paper reviews the potential link between finasteride's adverse effects and factors like hand preference and sexual orientation, emphasizing the need for personalized therapeutic approaches in treating male androgenic alopecia.

In this study, older women aged 70 and above, treated for sexual dysfunction using carefully monitored hormone therapy, reported improvements in sexual function and symptom relief, with no incidences of cancer or thromboembolic events, though some experienced breast tenderness and hair changes.

Man experienced sexual dysfunction, depression, breast growth, and skin discoloration after taking finasteride for hair loss.

This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.

This review examines reports of prolonged sexual dysfunction and depression associated with finasteride for male pattern hair loss, concluding that significant biases exist and further rigorous trials are needed to assess risks.

This study found that finasteride treatment in males with androgenetic alopecia was linked to significant changes in sperm parameters and increased testosterone levels, but no sexual dysfunction was observed, and sperm parameters returned to baseline after treatment stopped.

This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.

In this study, researchers observed that after 5 years of treatment, 89.9% of Korean men with androgenetic alopecia experienced improvement and 93.9% had prevention of disease progression with dutasteride 0.5mg, though sexual-related symptoms were common early but subsided over time.

Testosterone therapy can improve sexual function in women but long-term safety is unclear.

In this interventional study, researchers observed that women with stress urinary incontinence experienced significant symptom improvement one and three months after receiving autologous platelet-rich plasma injections, with no notable impact on sexual function or adverse reactions reported.

In this study, reports from individuals using Serenoa repens indicated a possible post-Serenoa syndrome characterized by persistent sexual and neuropsychiatric symptoms, with causality assessed as 'probable' in 54% of cases, highlighting an underrecognized safety concern that warrants further investigation.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

This study found that while finasteride effectively improves hair growth in male androgenetic alopecia, it may affect fertility at higher doses, and the evidence on its long-term sexual side effects is inconsistent and requires more rigorous research.

This review discusses the impact of testosterone therapy on postmenopausal women's sexual function and well-being but notes a lack of long-term safety studies and debates on defining androgen insufficiency.

This study analyzed self-reports from discussion forums to categorize and understand adverse effects experienced by individuals using finasteride, suggesting a need for further investigation into post-finasteride syndrome.

This study found that red ginseng oil (RXGIN) significantly improved lower urinary tract symptoms and some aspects of sexual function in men, with no serious adverse events reported.